KR20220120711A - 폐혈관 질환 치료용 조성물 및 방법 - Google Patents

폐혈관 질환 치료용 조성물 및 방법 Download PDF

Info

Publication number
KR20220120711A
KR20220120711A KR1020227028385A KR20227028385A KR20220120711A KR 20220120711 A KR20220120711 A KR 20220120711A KR 1020227028385 A KR1020227028385 A KR 1020227028385A KR 20227028385 A KR20227028385 A KR 20227028385A KR 20220120711 A KR20220120711 A KR 20220120711A
Authority
KR
South Korea
Prior art keywords
pro
leu
ser
gly
gls1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227028385A
Other languages
English (en)
Korean (ko)
Inventor
스테판 와이. 찬
토마스 베르테로
Original Assignee
유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션
더 브리검 앤드 우먼즈 하스피털, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션, 더 브리검 앤드 우먼즈 하스피털, 인크. filed Critical 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션
Publication of KR20220120711A publication Critical patent/KR20220120711A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020227028385A 2016-05-26 2017-05-25 폐혈관 질환 치료용 조성물 및 방법 Ceased KR20220120711A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662341848P 2016-05-26 2016-05-26
US62/341,848 2016-05-26
KR1020187037697A KR102434879B1 (ko) 2016-05-26 2017-05-25 폐혈관 질환 치료용 조성물 및 방법
PCT/US2017/034420 WO2017205595A1 (en) 2016-05-26 2017-05-25 Compositions and methods for treating pulmonary vascular disease

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187037697A Division KR102434879B1 (ko) 2016-05-26 2017-05-25 폐혈관 질환 치료용 조성물 및 방법

Publications (1)

Publication Number Publication Date
KR20220120711A true KR20220120711A (ko) 2022-08-30

Family

ID=60412630

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227028385A Ceased KR20220120711A (ko) 2016-05-26 2017-05-25 폐혈관 질환 치료용 조성물 및 방법
KR1020187037697A Active KR102434879B1 (ko) 2016-05-26 2017-05-25 폐혈관 질환 치료용 조성물 및 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187037697A Active KR102434879B1 (ko) 2016-05-26 2017-05-25 폐혈관 질환 치료용 조성물 및 방법

Country Status (8)

Country Link
US (2) US10925869B2 (enExample)
EP (2) EP3463574B1 (enExample)
JP (2) JP7079937B2 (enExample)
KR (2) KR20220120711A (enExample)
CN (2) CN115192719B (enExample)
AU (1) AU2017270092B2 (enExample)
CA (1) CA3025401A1 (enExample)
WO (1) WO2017205595A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115192719B (zh) * 2016-05-26 2024-03-01 匹兹堡大学联邦高等教育系统 用于治疗肺血管疾病的组合物和方法
JP7394463B2 (ja) * 2017-11-22 2023-12-08 ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション Ｙａｐ１／ｗｗｒｔ１阻害組成物およびｇｌｓ１阻害組成物を投与するための組成物および方法
JP7156856B2 (ja) * 2018-08-21 2022-10-19 国立大学法人富山大学 抗肥満剤
EP3690109B1 (en) 2019-02-01 2021-05-05 LG Electronics Inc. Laundry treating apparatus
EP3690108B1 (en) 2019-02-01 2021-05-12 LG Electronics Inc. Laundry treating apparatus
EP3690110B1 (en) 2019-02-01 2021-06-02 LG Electronics Inc. Laundry treating apparatus
WO2020226919A1 (en) * 2019-05-05 2020-11-12 Georgetown University Use of inhibitors of yap/taz for the treatment of cancer
US20220233542A1 (en) * 2019-06-05 2022-07-28 University Of Georgia Research Foundation Compositions and methods for preventing or treating human immunodeficiency virus associated pulmonary arterial hypertension
JP7514508B2 (ja) * 2020-05-19 2024-07-11 国立大学法人鳥取大学 胆道がん治療薬
US20240082158A1 (en) * 2020-05-21 2024-03-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compositions and methods for administering a yap1/wwrt1 inhibiting composition and a gls1 inhibiting composition
CN116421591A (zh) * 2023-05-10 2023-07-14 哈尔滨医科大学大庆分校 Ldha抑制剂在制备治疗肺动脉高压的药物中的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5798345A (en) 1990-09-21 1998-08-25 Bone Care International, Inc. Method of inhibiting the hyperproliferation of malignant cells
US5707608A (en) 1995-08-02 1998-01-13 Qlt Phototherapeutics, Inc. Methods of making liposomes containing hydro-monobenzoporphyrin photosensitizer
US5756541A (en) 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
US20050119330A1 (en) * 2003-03-17 2005-06-02 Kao Peter N. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases
US7943179B2 (en) 2003-09-23 2011-05-17 Massachusetts Institute Of Technology pH triggerable polymeric particles
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
US20090202540A1 (en) * 2008-02-11 2009-08-13 Auspex Pharmaceuticals, Inc. Substituted oxazaphosphorines
US8741861B2 (en) * 2008-03-27 2014-06-03 Vascular Biosciences Methods of novel therapeutic candidate identification through gene expression analysis in vascular-related diseases
KR100963435B1 (ko) 2008-06-19 2010-06-17 한국과학기술연구원 서방형 약물전달 및 조직재생용 덮인 다공성 생분해성고분자 미립구의 제조 방법
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
EP3520821A1 (en) 2012-04-02 2019-08-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
EP3116872A4 (en) 2014-03-14 2017-08-30 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
US20170226507A1 (en) 2014-05-05 2017-08-10 The Brigham And Women's Hospital, Inc. Coordinate control of pathogenic signaling by the mir-130/301 family in pulmonary hypertension and fibroproliferative diseases
US20160058759A1 (en) * 2014-07-03 2016-03-03 Board Of Regents, The University Of Texas System Glutaminase inhibitor therapy
WO2016007647A1 (en) 2014-07-09 2016-01-14 The Johns Hopkins University Glutaminase inhibitor discovery and nanoparticle-enhanced delivery for cancer therapy
CN114470207B (zh) * 2014-08-01 2023-09-19 布里格姆及妇女医院股份有限公司 与肺动脉高压的治疗有关的组合物和方法
WO2016054388A1 (en) 2014-10-03 2016-04-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Glutaminase inhibitors
WO2016077632A2 (en) * 2014-11-13 2016-05-19 Buck Institute For Research On Aging Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications
EP3256123B1 (en) 2015-02-12 2023-06-07 The Johns Hopkins University Inhibition of yap for breaking tumor immune tolerance
EP3316910A4 (en) 2015-07-02 2019-05-01 Children's Medical Center Corporation UPPER TRIPLET TRIPLET ANNIHILATION UPWARD IMPLEMENTATION
WO2017095751A1 (en) 2015-12-02 2017-06-08 Partikula Llc Compositions and methods for modulating cancer cell metabolism
CN115192719B (zh) 2016-05-26 2024-03-01 匹兹堡大学联邦高等教育系统 用于治疗肺血管疾病的组合物和方法
JP7394463B2 (ja) * 2017-11-22 2023-12-08 ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション Ｙａｐ１／ｗｗｒｔ１阻害組成物およびｇｌｓ１阻害組成物を投与するための組成物および方法

Also Published As

Publication number Publication date
JP2019519533A (ja) 2019-07-11
CN109843378A (zh) 2019-06-04
JP7411967B2 (ja) 2024-01-12
US11672795B2 (en) 2023-06-13
AU2017270092B2 (en) 2022-04-14
EP3463574A4 (en) 2020-07-29
KR20190013926A (ko) 2019-02-11
EP3463574B1 (en) 2021-11-03
EP3970720B1 (en) 2023-07-05
US10925869B2 (en) 2021-02-23
CN109843378B (zh) 2022-06-10
US20190298710A1 (en) 2019-10-03
CN115192719B (zh) 2024-03-01
JP7079937B2 (ja) 2022-06-03
CN115192719A (zh) 2022-10-18
KR102434879B1 (ko) 2022-08-22
JP2022119825A (ja) 2022-08-17
EP3970720A1 (en) 2022-03-23
CA3025401A1 (en) 2017-11-30
US20210154187A1 (en) 2021-05-27
EP3463574A1 (en) 2019-04-10
AU2017270092A1 (en) 2018-12-06
WO2017205595A1 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
KR102434879B1 (ko) 폐혈관 질환 치료용 조성물 및 방법
Song et al. CREG protects from myocardial ischemia/reperfusion injury by regulating myocardial autophagy and apoptosis
Wu et al. Recombinant adiponectin peptide promotes neuronal survival after intracerebral haemorrhage by suppressing mitochondrial and ATF4‐CHOP apoptosis pathways in diabetic mice via Smad3 signalling inhibition
EP3878470A1 (en) Method for removing senescent cell, and method for preparing senescent cell
AU2017281980B2 (en) Wnt inhibitors for use in the treatment of fibrosis
AU2016293834A1 (en) MCJ inhibitors for use in treating drug-induced diseases and conditions
WO2021151079A1 (en) Modulating lymphatic vessels in neurological disease
US20210330744A1 (en) Methods and Compositions for Treating Neurodegeneration and Fibrosis
KR102536092B1 (ko) Lrp5 발현 또는 활성 억제제를 포함하는 허혈성 심장질환의 예방 또는 치료용 약학적 조성물
AU2022203624A1 (en) Compositions and methods for treating pulmonary vascular disease
HK40006997B (en) Compositions and methods for treating pulmonary vascular disease
KR101264650B1 (ko) 심장비대 방지용 조성물 및 이를 포함하는 심장비대증 치료제
US20240307283A1 (en) Compositions and methods for decreasing pigmentation
US20250163141A1 (en) Ccl4 antagonist for inhibiting vascular aging
Vigil The Role of Aconitate Decarboxylase 1 in Inflammation and Disease
Malhi Use of SRPK1 inhibitors for the treatment of Diabetic Retinopathy
Guo Regulation of Ribosome Biogenesis and Skeletal Muscle Size Control
KR20220118195A (ko) 대사성 글루타메이트 수용체 5가 활성화된 자연 살해 세포 및 이의 용도
Mehta Molecular Regulation of Follistatin by Caveolin-1 in Glomerular Mesangial Cells and its Therapeutic Potential in Chronic Kidney Disease
WO2021096911A1 (en) Gene delivery systems for treatment of heart failure
Richards The Role of NADPH Oxidase-2 in the Development of Cardiac Fibrosis
Brown Overcoming adversity: Correction of aberrant tissue growth preserves homeostasis in the skin
Eichelbaum et al. MAMMALIAN PEPTIDE TRANSPORTERS AS TARGETS FOR DRUG DELIVERY
HK1241730B (zh) 治疗癌症干细胞的组合物

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220817

Application number text: 1020187037697

Filing date: 20181226

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220913

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230111

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20230410

Patent event code: PE09021S02D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230802

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230410

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20230111

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I